Navigation Links
Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference
Date:11/12/2009

PRINCETON, N.J. and SAN DIEGO, Nov. 12 /PRNewswire/ -- Tobira Therapeutics, a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two double-blind, placebo-controlled studies of TBR-652 in eighty-four healthy volunteers. The two studies, a single-ascending dose (SAD) study and the multiple-ascending dose (MAD) study, were undertaken to assess the pharmacokinetics, safety and tolerability of TBR-652 in two tablet formulations under fasted and fed conditions, respectively. In the SAD study 2 cohorts of 12 subjects were randomized per dose level; each subject received up to 3 single escalating doses of study drug. Dosing followed an overnight fast of at least 8 hours. In the MAD study, 5 dose groups of 12 subjects each were randomized to receive drug daily for 10 days. Doses were either in the same formulation as the SAD study (F1) or a newer formulation (F2). Doses were taken within 10 minutes after completion of a standard high-fat breakfast. Subjects in both studies were followed for 10 days after the last dose of TBR-652.

TBR-652 was readily absorbed in both tablet formulations achieving mean peak plasma concentrations in 4-6 hours. A 25 mg/day F1 or F2 tablet achieved plasma exposures greater than the target therapeutic level of 2ng/mL projected from in vitro studies of TBR-652. TBR-652 was eliminated from plasma with linear kinetics and similar half-lives (mean approximately 35-40 hours) across dose levels. This elimination half-life is sufficiently long to support once-daily dosing.

TBR-652 was well-tolerated at single daily doses up to 800 mg and once-daily doses of up to 200 mg for 10 days. Headache, diarrhea, abdominal pain and nausea were the most commonly encountered treatment-emergent events; all AEs resolved by the end of both studies. "The results fro
'/>"/>

SOURCE Tobira Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV
2. Tobira Therapeutics Inc. Receives US Patent for TBR-652
3. Reportlinker Adds Pain Therapeutics 2005: Market Dynamics and Outlook
4. Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009
5. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
6. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
7. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
8. Echo Therapeutics Announces Significant Advance in Development of its One-Piece, Needle Free Symphony tCGM Biosensor
9. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
10. Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study
11. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:7/10/2014)... (PRWEB) July 10, 2014 Register to ... DataSite recently streamed the live webinar ‘Capitalizing on the ... from a group of several M&A experts in the ... the broader energy transaction marketplace. These experts shared their ... the deal market in this sector has been revitalized. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 ... and believes that having family close by during ... difference in whether or not the process is ... of its website at http://www.bestdrugrehabilitation.com/success-stories/ . , ... and video testimonials from several Best Drug Rehabilitation ...
(Date:7/10/2014)... AURORA, Colo. (July 8, 2014) A new study ... some modest improvements, poor oral health remains a major ... overall. , "The oral health among Native Americans is ... the rest of the country," said Terrence Batliner, DDS, ... Health Research at the School of Public Health. "The ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Adults with dyslexia are ... as children or teenagers than people who don,t have ... Dyslexia, which affects up to 10 percent of ... that 35 percent of adults with this condition said ... 7 percent of those without dyslexia. "Even after ...
(Date:7/10/2014)... Thompson HealthDay Reporter THURSDAY, ... wars that break out regularly between outspoken celebrities or loudmouth ... own relationship, a new study suggests. High amounts of ... if the couple is in a long-term relationship, according to ... In turn, that friction can lead to cheating and breakups, ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3
... from avian flu, bringing the total number of deaths from ... 27, a Tangerang resident, died late Friday and Jakarta resident ... two and three days of treatment in a hospital here ... flu," said an official at the Indonesian health ministry. ...
... a secret so painful that they even keep it from ... the University of Virginia, the secret exists, //and it’s big. ... high expectations for almost every area of their lives, too ... who is one of the world’s preeminent experts on women’s ...
... graduate student in the Section of Microbial Pathogenesis at ... path taken by Campylobacter// jejuni (campylobacter), as it infects ... the most common causes of diarrhea worldwide, strikes 2.4 ... few unpleasant days, but it can be life threatening ...
... prevailing trend among kids of today, who have turned ... options.// ,Researchers from university of waterloo conducted ... about eating wrong from a tender age. Parents ... which is a leading cause of increasing obesity rates, ...
... knows that a diet laden with fats and sugar, combined ... smoking is a recipe for// major problems including diabetes and ... need to realize that those same bad habits in children ... road. ,The good news: The fix is ...
... findings of a study appearing in the January 2007 issue ... discovered histamine,// the inflammatory compound released during allergic reactions that ... ,They say that histamine can be produced in large amounts ... that is the major component of pus. Pus, a fluid ...
Cached Medicine News:Health News:Women's Sex Lives Mediocre 2Health News:The Uncommon Pathway of Campylobacter Jejuni 2Health News:Cure for Most Heart Attacks Is Free, but It's Important to Start Young 2Health News:Cure for Most Heart Attacks Is Free, but It's Important to Start Young 3Health News:WBC in Lung Produces Histamine: Study 2Health News:WBC in Lung Produces Histamine: Study 3
Foldable Hydrophilic IOL with UV Absorber....
The STAAR ELASTIC LENS®, is a single piece silicone lens to be placed completely in the capsular bag....
... Engineers at Pfizer used wavefront sensing ... Optic Technology. Innovative TECNIS features a patented ... spherical aberration, which compensates for the positive ... result, TECNIS is the first and only ...
... PhacoFlexII SI30NB is foldable silicone ... it's patients. It is used ... SI30NB is indicated for primary ... of aphakia in adults (over ...
Medicine Products: